Atezolizumab Plus Bevacizumab Versus Lenvatinib for HCC Stratified by CRAFITY Score

994 patients with unresectable hepatocellular carcinoma were analyzed in a retrospective international multicenter study from September 2017 to March 2024. The dataset compares progression-free and overall survival between two first-line treatments, atezolizumab plus bevacizumab and lenvatinib, stratified by the baseline CRAFITY score. The study was published on figshare by figshare admin karger under a CC-BY-4.0 license.

Use Cases

• Compare progression-free survival between treatment regimens based on CRAFITY score stratification.
• Analyze overall survival outcomes for patients with unresectable hepatocellular carcinoma.
• Investigate the interaction between the CRAFITY biomarker and first-line treatment efficacy.
• Validate the CRAFITY score as a tool for guiding first-line treatment selection in clinical practice.

Strengths

• Dataset includes 994 patient records from an international cohort across 24 hospitals.
• Study spans a significant time range from September 2017 to March 2024.
• Analysis is stratified by a specific biomarker score (CRAFITY) with three defined categories.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect geographic bias inherent to the specific hospitals in Japan and Taiwan.

Provenance

Source

figshare admin karger

Collection Method

Retrospective analysis of patient records from 11 hospitals in Japan and 13 hospitals in Taiwan.

Time Range

September 2017 to March 2024

Freshness

Last updated 2026-06-01 07:55:21; freshness should be verified.

Geography

Japan and Taiwan